The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia

Tumor cells promote the suppression of host anti-tumor type 1 T cell responses by various mechanisms, including the upregulation of surface inhibitory molecules such as programmed death ligand (PD-L)-1, and the production of immunosuppressive cytokines such as interleukin-10 (IL-10). There are over...

Full description

Bibliographic Details
Main Authors: Laura Jimbu, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, Ciprian Tomuleasa, Delia Dima, Corina Bocsan, Mihnea Zdrenghea
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Pharmaceuticals
Subjects:
PD-1
PD-L1
IL-10
acute myeloid leukemia
cancer
Online Access:https://www.mdpi.com/1424-8247/14/11/1105

Similar Items

Similar Items